← All companies

DMAC

DiaMedica Therapeutics Inc.

DMAC Nasdaq Pharmaceutical Preparations EDGAR ↗

$6.52

+0.01 +0.15%

Key statistics

from XBRL data in SEC filings

Market cap

$351M

Revenue (TTM)

$500K

Net income (TTM)

-$35.1M

EPS (TTM)

$-0.71

P/E ratio

—

Dividend yield

—

Free cash flow

-$29.1M

Cash

$4.87M

Total assets

$53.1M

Gross margin

—

52-week range

$4.15 – $10.42

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Shareholder vote results May 21, 2026 10-Q Quarter ended 2026-03-31 May 6, 2026 8-K Results of operations (earnings release) May 6, 2026 8-K Results of operations (earnings release) Mar 31, 2026 10-K Fiscal year ended 2025-12-31 Mar 30, 2026 8-K Other events Jan 5, 2026 8-K Regulation FD disclosure; Other events Dec 18, 2025 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release) Nov 12, 2025 8-K Entered a material agreement Aug 12, 2025 10-Q Quarter ended 2025-06-30 Aug 12, 2025 8-K Results of operations (earnings release) Aug 12, 2025 8-K Director or officer change; Regulation FD disclosure; Other events Aug 6, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Jul 21, 2025 8-K Regulation FD disclosure Jul 17, 2025 8-K Shareholder vote results May 15, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release) May 13, 2025 10-K Fiscal year ended 2024-12-31 Mar 17, 2025 8-K Results of operations (earnings release) Mar 17, 2025 8-K Director or officer change Mar 6, 2025 8-K Director or officer change; Regulation FD disclosure Feb 24, 2025 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release); Regulation FD disclosure Nov 13, 2024 8-K Results of operations (earnings release) Aug 7, 2024 10-Q Quarter ended 2024-06-30 Aug 7, 2024 8-K Entered a material agreement; Unregistered sale of equity; Other events Jun 26, 2024 8-K Regulation FD disclosure; Other events Jun 26, 2024 8-K Director or officer change; Shareholder vote results May 23, 2024 10-Q Quarter ended 2024-03-31 May 8, 2024 8-K Results of operations (earnings release) May 8, 2024 8-K Director or officer change Apr 10, 2024 10-K Fiscal year ended 2023-12-31 Mar 19, 2024 8-K Results of operations (earnings release) Mar 19, 2024 10-Q Quarter ended 2023-09-30 Nov 13, 2023 8-K Results of operations (earnings release); Regulation FD disclosure Nov 13, 2023 8-K Director or officer change Sep 5, 2023 10-Q Quarter ended 2023-06-30 Aug 14, 2023 8-K Results of operations (earnings release) Aug 14, 2023 8-K Entered a material agreement; Unregistered sale of equity; Other events Jun 21, 2023